With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Johnson & Johnson (NYSE:JNJ) to report quarterly earnings at $2.46 per share on revenue of $24.16 billion before the opening bell, according to data from Benzinga Pro. Johnson & Johnson shares slipped 0.3% to $217.50 in after-hours trading.GameStop Corp. (NYSE:GME) shares rose in Tuesday's extended trading after CEO Ryan Cohen disclosed a massive purchase ...

Johnson & Johnson (NYSE:JNJ) will release earnings for the fourth quarter before the opening bell on Wednesday, Jan. 21.Analysts expect the company to report fourth-quarter earnings of $2.47 per share. That’s up from $2.04 per share in the year-ago period. The consensus estimate for Johnson & Johnson’s quarterly revenue is $24.16 billion (it reported $22.52 billion last year), according to Benzinga Pro.As per the recent news, Johnson & Johnson, on Jan. 14, shared topline results from the investigational Pha ...

Earnings Report - Johnson & Johnson is set to release its fourth-quarter earnings on January 21, with analysts expecting earnings of $2.47 per share, an increase from $2.04 per share in the same period last year [1] - The consensus estimate for quarterly revenue is $24.16 billion, up from $22.52 billion reported last year [1] Clinical Study Update - On January 14, Johnson & Johnson shared topline results from the Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple myeloma, a type of blood cancer [2] - Following this news, shares of Johnson & Johnson fell by 0.2%, closing at $218.21 [2] Analyst Ratings - Bernstein analyst Lee Hambright maintained a Market Perform rating and raised the price target from $193 to $208 [4] - Barclays analyst Matt Miksic maintained an Equal-Weight rating and raised the price target from $197 to $217 [4] - Goldman Sachs analyst Asad Haider maintained a Buy rating and increased the price target from $213 to $240 [4] - B of A Securities analyst Tim Anderson maintained a Neutral rating and raised the price target from $204 to $220 [4] - Morgan Stanley analyst Terence Flynn maintained an Equal-Weight rating and raised the price target from $190 to $197 [4]

In a victory for thousands of women suing Johnson & Johnson over claims that the company’s baby powder and other talc products caused their ovarian cancer, a US federal judge has ruled to allow testimony from experts who support the link. The ruling from an outside judge serving as a special master in the long-running litigation, which includes more than 67,500 lawsuits ​that have been consolidated in federal court in New Jersey, will allow the cases to move towards the first trial in federal court potentia ...

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Stocks fell sharply and bond yields spiked higher on Tuesday after President Donald Trump announced over the weekend that he will put 10% tariffs, beginning Feb. 1, on a bunch of European Union nations that oppose his plan to purchase Greenland, an autonomous territory of the Kingdom of Denmark. Trump said those tariffs will escalate to 2 ...

Johnson & Johnson (NYSE:JNJ) is one of the stocks on Jim Cramer’s game plan for this week. Cramer explained why he sold the stock for the Charitable Trust, as he commented: "Wednesday morning brings two stocks that are hard to keep down. Johnson & Johnson and Charles Schwab. J&J has become a pure play on pharma by spinning off its orthopedics division. That’s smart because orthopedics happens to be a commoditized business. Meanwhile, its pharma business has some of the best drugs in the pipe, and they rea ...

J&J announced plans to separate its Orthopaedics business into a standalone company called DePuy Synthes. The move will be completed within 18 to 24 months."Our surgical technologies are used in most operating rooms globally. And in Q3, we delivered more than 9% growth in biosurgery and almost 7% in wound closure, driven by accelerating adoption of our latest innovations," Schmid said.Tim Schmid, Executive Vice President of MedTech at J&J, emphasized the company's commitment during the recent earnings call ...

Core Viewpoint - Johnson & Johnson (JNJ) is positioned as a leader in the healthcare sector, with strong growth driven by its pharmaceutical and MedTech divisions, despite facing some market challenges [1][2][6] Financial Performance - Analysts project JNJ's earnings per share (EPS) for the upcoming quarterly earnings to be $2.49, with revenue expected to reach approximately $24.16 billion [1][6] - The Zacks Consensus Estimate forecasts fourth-quarter sales at $24.14 billion and EPS at $2.50, indicating alignment with Wall Street projections [2] - JNJ aims for over 5% revenue growth in 2026, although earnings estimates for 2025 and 2026 have seen slight declines [3] Market Position - JNJ maintains a strong financial position, reflected in a P/E ratio of 21.14, which indicates investor confidence in its earnings potential [4][6] - The company's price-to-sales ratio stands at 5.72, and the enterprise value to sales ratio is 6.02, highlighting its market valuation [4] - An enterprise value to operating cash flow ratio of 22.90 underscores JNJ's cash flow efficiency [4] Debt and Investment Metrics - JNJ's debt-to-equity ratio is 0.58, demonstrating a balanced approach to financing [5] - A current ratio of 1.07 indicates the company's capability to meet short-term obligations [5] - With an earnings yield of 4.73%, JNJ offers a solid return on investment, reinforcing its status as a reliable player in the healthcare industry [5]

分组1 - Johnson & Johnson is set to release its fourth-quarter earnings on January 21, with expected earnings of $2.47 per share, an increase from $2.04 per share in the same period last year [1] - The consensus estimate for the company's quarterly revenue is $24.16 billion, up from $22.52 billion reported last year [1] - The company recently shared topline results from the Phase 3 MajesTEC-9 study of Tecvayli for multiple myeloma, which may attract investor interest [2] 分组2 - Johnson & Johnson has an annual dividend yield of 2.38%, translating to a quarterly dividend of $1.30 per share, or $5.20 annually [2] - To generate a monthly income of $500 from dividends, an investor would need to own approximately 1,154 shares, equating to a total investment of about $252,334 [3][4] - For a more conservative monthly income goal of $100, an investor would need 231 shares, requiring an investment of around $50,510 [4] 分组3 - The dividend yield is calculated by dividing the annual dividend payment by the current stock price, which can fluctuate based on stock price changes [5] - If the stock price increases, the dividend yield decreases, and if the stock price decreases, the dividend yield increases [5] - Johnson & Johnson's shares fell by 0.4% to close at $218.66 recently [6]

分组1 - Johnson & Johnson is set to release its fourth-quarter earnings on January 21, with expected earnings of $2.47 per share, an increase from $2.04 per share in the same period last year [1] - The consensus estimate for Johnson & Johnson's quarterly revenue is $24.16 billion, up from $22.52 billion reported last year [1] - The company recently shared topline results from the Phase 3 MajesTEC-9 study of Tecvayli for multiple myeloma, indicating ongoing research and development efforts [2] 分组2 - Johnson & Johnson has an annual dividend yield of 2.38%, translating to a quarterly dividend of $1.30 per share, or $5.20 annually [2] - To achieve a monthly income of $500 from dividends, an investor would need to own approximately 1,154 shares, equating to a total investment of about $252,334 [3][4] - For a more conservative monthly income goal of $100, an investor would need 231 shares, requiring an investment of around $50,510 [4] 分组3 - The dividend yield is calculated by dividing the annual dividend payment by the current stock price, which can fluctuate and affect the yield [5] - Changes in the stock price can lead to variations in the dividend yield; for instance, if the stock price rises, the yield decreases, and vice versa [5] - Johnson & Johnson's shares fell by 0.4% to close at $218.66 recently, reflecting market activity [6]